P-041 - Patterns of failure in pancreatic cancer: results review

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Pancreatic Cancer
Presenter M.V. de Torres Olombrada
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors M.V. de Torres Olombrada1, I. Juez Martel2, T. Garcia Canibano2, D. Gutierrez Abad2, C. Rodriguez Rodriguez2, F. Pereira Perez2
  • 1H Universitario Fuenlabrada, Fuenlabrada/ES
  • 2H U Fuenlabrada, Fuenlabrada/ES

Abstract

Introduction

Pancreatic cancer is one of the malignant diseases which shows a higher failure rate with a 5 year overall survival under 5%. The aim of this review is to analyze the patterns of relapse of patients diagnosed of pancreatic cancer and treated with combined radiochemotherapy in our institution.

Methods

During 2011 and 2012 a total of 17 patients with pancreatic cancer have been treated with chemoradiotherapy in our institution, (10 male, 7 female). Location of the primary tumour was pancreatic head in 13 of them and body or tail in 4.

Nine patients received adjuvant postoperative radiochemotherapy, 1 neoadjuvant treatment and 8 radiochemotherapy as exclusive radical treatment. Radiotherapy treatment was delivered with IMRT/IGRT technique to a total dose of 50.4 Gy (1.8 Gy per fraction) and concurrent chemotherapy was based on weekly gemcitabine.

Results

At the date of our analysis 47% of patients had developed distant metastases, just 11.7% local relapse (2 patients relapsed within the RT field and one had a marginal relapse), 2 patients had tumour markers rise without relapse evidence and one patient had a mixed (local and distant) pattern of failure. Five patients died and four are free of disease relapse (all these 4 belong to the adjuvant treatment group).

Conclusion

IMRT/IGRT in combination with weekly gemcitabine seem to be a good treatment choice as adjuvant postoperative treatment, which may decrease the local relapse rate in these patients. Local failure most frequent areas are the surrounding vessels tissues.